Formycon AG provided earnings guidance for the year 2023. For the year, the company expects a significant increase of revenues compared to fiscal 2022, resulting from revenue and earnings contributions from the commercialization of the Lucentis biosimilar (FYB201) Ranivisio^3/Ongavia^4 /CIMERLI^5 as well as anticipated milestone payments for the FYB202 project.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.95 EUR | +0.63% | +3.36% | -29.17% |
Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.17% | 753M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- Formycon AG Provides Earnings Guidance for the Year 2023